Paul Andrew Moore, Chief Scientific Officer of Zymeworks Inc., filed a Form 4 on November 16, 2026, disclosing the exercise of stock options and sale of common stock transactions dated November 13, 2026.

Key Highlights

  • Option exercise: Moore exercised 25,000 stock options on November 13, 2026, at an exercise price of $5.82 per share, acquiring 25,000 shares of common stock.
  • Three sell transactions: Moore disposed of a total of 39,741 shares across three separate sales on November 13, 2026, at weighted average prices of $26.14, $26.09, and $26.04.
  • Remaining direct ownership: Following all reported transactions, Moore directly held 33,756 shares of common stock, according to the filing.
  • Derivative securities: Moore retained 175,000 stock options (right to buy) with an exercise price of $5.82 and an expiration date of July 17, 2032, after the reported exercise.
  • Vesting schedule: The stock options vest with 25% of underlying shares on the first anniversary of the grant date, and the remainder in 36 equal monthly installments on the last day of each month following that anniversary.
  • Weighted average prices: The three sales were executed in multiple transactions; actual per-share prices ranged from $25.95 to $26.21 across the three tranches.

Moore's Option Exercise and Common Stock Sales at Zymeworks

According to the Form 4 filed with the SEC on November 16, 2026, Paul Andrew Moore, identified as Chief Scientific Officer of Zymeworks Inc. (NASDAQ:ZYME), reported four transactions in the company's common stock on November 13, 2026. The filing was submitted by Catherine Graham as attorney-in-fact on Moore's behalf.

The first transaction was an option exercise (transaction code M) in which Moore acquired 25,000 shares of common stock at $5.82 per share from a stock option granted with an expiration date of July 17, 2032. Following that acquisition, Moore held 73,497 shares directly. Three subsequent sale transactions (transaction code S) then reduced his holdings: 7,367 shares were sold at a weighted average price of $26.14, with individual transaction prices ranging from $26.07 to $26.21; 7,374 shares were sold at a weighted average of $26.09, with prices ranging from $26.05 to $26.15; and 25,000 shares were sold at a weighted average of $26.04, with prices ranging from $25.95 to $26.11. All sales are reported as direct ownership disposals.

After all four transactions, Moore's direct beneficial ownership in Zymeworks common stock stood at 33,756 shares, as reported in the filing. His remaining derivative holdings consist of 175,000 stock options with a $5.82 exercise price, all held directly. The filing does not indicate whether the sales were made pursuant to a Rule 10b5-1 plan, as that box was not checked on the form.

What Was Disclosed

The filing disclosed an option exercise of 25,000 shares and three open-market sales totaling 39,741 shares of Zymeworks Inc. common stock by Chief Scientific Officer Paul Andrew Moore on November 13, 2026, leaving him with 33,756 shares directly held.